Modifications to Trp dendrimers yielded compounds with potent, specific antiviral activity against HIV and EV71, and a new convergent synthetic approach improved efficiency.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Trp-dendrimer antivirals; leaves open optimal design and in vivo validation before any therapeutic consideration.
We have recently described a new class of dendrimers with tryptophan (Trp) on the surface that show dual antiviral activities against HIV and EV71 enterovirus. The prototype compound of this family is a pentaerythritol derivative with 12 Trps on the periphery. Here we complete the structure-activity relationship studies of this family to identify key features that might be significant for the antiviral activity. With this aim, novel dendrimers containing different amino acids (aromatic and non-aromatic), tryptamine (a "decarboxylated" analogue of Trp) and N-methyl Trp on the periphery have been prepared. Dendrimer with N-Methyl Trp was the most active against HIV-1 and HIV-2 while dendrimer with tyrosine was endowed with the most potent antiviral activity against EV71. This tyrosine dendrimer proved to inhibit a large panel of EV71 clinical isolates (belonging to different clusters) in the low nanomolar/high picomolar range. In addition, a new synthetic procedure (convergent approach) has been developed for the synthesis of the prototype and some other dendrimers. This convergent approach proved more efficient (higher yields, easier purification) than the divergent approach previously reported.
No takes yet. Share an insight, caveat, or question.
Martínez-Gualda et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: